Company intelligence / Profile preview

Quibiotic

Évry, Île-de-France, Franceventureradar.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quibiotic has developed three molecular synthesis platforms enabling innovative modifications of β-lactam rings to create new anti-infective and anticancer compounds. Experimental trials have shown class D β-lactamase inhibition for one molecule and antineoplastic activity for another. The company is collaborating with academic partners to study substrate complexation with cyclodextrins to modulate bioavailability or activity of their compounds

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules (specifically, novel β-lactam derivatives and conjugates)
Industry: Biotech

Partnerships

University of Évry–Paris Saclay and Professor N. Jarroux at Lambe laboratory for research on cyclodextrin complexation and modulation of compound bioavailability/activity

Beyond the preview

Go deeper on Quibiotic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quibiotic.

Explore the full profile